Meir Azulay
CEO
Claimed by owner Bio-XL
Former names:
AI for the Early Prediction of Breast Cancer
Bio-XL
About
Bio-XL is a preclinical-stage drug development company developing new drug entities based on in-licensed technologies, from the early stage to the late-clinical and commercial stages.
The company is working toward an anticancer drug treatment based on the Klotho hormone, with a novel mechanism of action for triple-negative breast cancer and pancreatic cancer, as well as breast cancer prediction using digital pathology and artificial intelligence.
Bio-XL has a worldwide exclusive license for the commercialization of the technologies based on intellectual property from Sheba Medical Center in Israel and Cedars-Sinai Medical Center in the U.S.
The company is working toward an anticancer drug treatment based on the Klotho hormone, with a novel mechanism of action for triple-negative breast cancer and pancreatic cancer, as well as breast cancer prediction using digital pathology and artificial intelligence.
Bio-XL has a worldwide exclusive license for the commercialization of the technologies based on intellectual property from Sheba Medical Center in Israel and Cedars-Sinai Medical Center in the U.S.
Primary Sector
Life Sciences & HealthTech
Products
CancerPredict, Klothix
Geographic markets
-
Funding
Total Funding
Undisclosed
Last Funding
Undisclosed
Funding Stage
Total Rounds
0
Investors
0
News
(0)The Team
(3)
MA
OF
Ouri Fischel
COO
AL
Avraham Laban
CTO & Portfolio Manager
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Media gallery
(0)Locations
Israel
Nachal Snir St 15, Yavne, Israel
Locations
Israel
Nachal Snir St 15, Yavne, Israel
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,